A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
← catalyst calendarNCT05821855 · readout ≤ 1,441 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
120actual
Sites
13
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-09 | actual | When the study began enrolling |
| Primary completion | Jul 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Open-angle Glaucoma
- OAG
Interventions
- Device: XEN45 Glaucoma Treatment System
- Procedure: Trabeculectomy
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in Intraocular Pressure (IOP)
measured Baseline to Month 12
Number of Participants with Adverse Events (AEs)
measured Baseline to Month 60
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed